Fluoroquinolones in paediatrics

Paediatric Drugs

Volumn 3, Issue 5, 2001, Pages 365-377

  Gendrel, D ^a   Moulin, F ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; CENTRAL NERVOUS SYSTEM INFECTION; CYSTIC FIBROSIS; DRUG PENETRATION; EAR NOSE THROAT DISEASE; FEBRILE NEUTROPENIA; GASTROINTESTINAL INFECTION; GRAM NEGATIVE INFECTION; IMMUNE DEFICIENCY; MYCOBACTERIOSIS; MYCOBACTERIUM; NEWBORN INFECTION; PRIORITY JOURNAL; REVIEW; SALMONELLA; SHIGELLA; URINARY TRACT INFECTION;

EID: 0034992984     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103050-00005     Document Type: Review

References (70)

1. Survey of unlicensed and off label drug use in paediatric wards in European countries. European network for drug investigation in children
2. The use of fluoroquinolones in pediatrics: A reassessment
3. Trends in bacterial resistance to fluoroquinolones
4. New uses for new and old quinolones and the challenge of resistance
5. Emergence and dissemination of quinolone-resistant Escherichia coli in the community
6. Multicenter in vitro comparative study of fluoroquinolones in 25,129 gram-positive and gram-negative clinical isolates
7. Epidemiology of quinolone resistance: Europe and North and South America
8. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multiresistant: Salmonella typhi in India
9. Quinolone-resistant salmonella typhi in Vietnam: Molecular basis if resistance and clinical response to treatment
10. Increasing fluoroquinolone resistance in salmonella serotypes in Finland during 1995-1997
11. An outbreak of multidrug-resistant, quinolone-resistant salmonella enterica serotype typhimurium DT104
12. Quinolone resistance among salmonella enterica from cattle, broilers, and swine in Denmark
13. Decreased susceptibility of streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network
14. Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children
15. Single dose safety and pharmacokinetics (PK) of oral gatifloxacin in pediatric patients
16. Safety of ciprofloxacin in children: Worldwide clinical experience based on compassionate use: Emphasis on joint evaluation
17. Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use-safety report
18. Ciprofloxacin in neonates and its possible adverse effect on the teeth
19. Side effects of pefloxacin in idiopathic nephrotic syndrome
20. Hypertension intracrânienne chez un nouveau-né traité par quinolones
21. Toxicité articulaire des quinolones
22. Fluoroquinolones toxicity profiles: A review focusing on newer agents
23. Quinolone arthropathy in animals versus children
24. Effects of ciprofloxacin and floxacin on adult human cartilage in vitro
25. Nalicixic acid in children: Retrospective matched controlled study for cartilage toxicity
26. Growth and joint symptoms in children treated with nalidixic acid
27. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin
28. Morphologic studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients
29. Retrospective review of ciprofloxacin for the treatment of acute pulmonary exarcebation in the pediatric CF patient
30. Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones
31. Achilles tendinitis induced by pefloxacin and other fluoroquinolone derivates
32. Pénétration et activité cellulaire des fluoroquinolones
33. A population based study of quinolones and the risk of achilles tendon rupture
34. Ciprofloxacin safety in pediatric population
35. Safety of long-term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review
36. Enquête rétrospective sur l'utilisation des fluoroquinolones en pédiatrie
37. Use of fluoroquinolones in pediatrics: Consensus report of an international society of chemotherapy commission
38. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations
39. Oral ciprofloxacin vs. intravenous ceftazidime plus tobramycin in pediatric cystic fibrosis patients: Comparison of antipseudomonas efficacy and assessment of safety with ultrasonography and magnetic resonance imaging
40. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytoprenic cancer patients with lymphomas and solid tumors
41. Norfloxacin in the prophylaxis of bacterial infections in neutropenic children
42. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients
43. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
44. Use of fluoroquinolones as prophylactic agents in patients with neutropenia
45. Ciprofloxacin in neonatal enterobacter cloacae septicaemia
46. The treatment of neonatal meningitis due to gram negative bacilli with ciprofloxacine: Evidence of satisfactory penetration into the CSF
47. Use of ciprofloxacin in an infant with ventriculitis
48. Méningites néonatales: Place des fluoroquinolones
49. Cardiac toxicity of intravenous erythromycin lactobionate in preterm infants
50. Chronic otitis media treated topically with ciprofloxacin or tobramycin
51. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: Preliminary experience in 21 children
52. The antibiotic treatment of acute otitis media and sinusitis in children
53. Evaluation of norfloxacin in the pediatric field
54. Using quinolones in urinary tract infections in children
55. Ciprofloxacin for the treatment of severe typhoid fever in children
56. An open study of ciprofloxacin for the treatment of proven or suspected extra-intestinal salmonellosis in African children
57. Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric treatment of acute invasive diarrhea in children
58. Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis
59. Eradication of convalescent salmonella carriage in children using two oral doses of pefloxacin
60. Response to antimicrobial therapy for shigellosis in Thailand
61. Double-bind, randomized clinical trial for safety and efficacy of norfloxacin for shigellosis in children
62. One-dose treatment with pefloxacin for infection due to multidrug-resistant shigella dysenteriae type 1 in Burundi
63. Treatment of shigellosis, III: Comparison of one and two dose ciprofloxacin with standard 5 day treatment. A randomized, blinded trial
64. Short treatment with pefloxacin in madagascan children with shigellosis due to multiresistant organisms
65. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases
66. A randomized, controlled trial of oral or IV trovafloxacin vs. ceftriaxone in the treatment of epidemic meningococcal meningitis
67. Use of quinolones in children with bacterial meningitis (BM): A comparative study of trovofloxacin and ceftriaxone ± vancomycin
68. Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis